Turning Point TherapeuticsAktie

ISIN: US90041T1088 | WKN: A2PGMX | Symbol: TPTX
58,70
 
USD
06.08.20 Nasdaq
+1,45 %
+0,84 USD
Geldkurs 06.08.20
58,70 USD
200 Stk.
Briefkurs 06.08.20
58,93 USD
1.800 Stk.
Mehr Daten anzeigen
Smartbroker
NewsFlashAnzeige
DURCHBRUCH für Biotech-Aktie! Klinische Studie ist auf dem Weg zur medizinischen Revolution! Investieren Sie in den Marktführer!

Turning Point Therapeutics Chart

Neuigkeiten zur Turning Point Therapeutics Inc Aktie

ZeitTitel
SmartbrokerJetzt auf smartbroker.de - ab 0 € pro Order handeln! Anzeige
27.07.20
Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources
13.07.20
Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer
07.07.20
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
22.06.20
Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models
01.06.20
Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast
29.05.20
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046
27.05.20
Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
19.05.20
Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
18.05.20
Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock
12.05.20
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response
04.05.20
Turning Point Therapeutics to Host First Quarter Conference Call
16.04.20
Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung Cancer
16.03.20
TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS
02.03.20
Turning Point Therapeutics to Host Fourth-Quarter, Full-Year 2019 Conference Call

Insidertrade: :
Hier Upload von Dokumenten / Links zum Wertpapier: Upload

Nachrichten aus der Branche Biotechnologie

ZeitTitel
06.08.20
Studies on COVID-19 Disease Susceptibility in China Using Bionano Genomics’ Saphyr Are Progressing and Generating High Quality Data
06.08.20
10x Genomics to Participate in the UBS Genomics 2.0 and Medtech Innovations Summit
06.08.20
AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock
06.08.20
ProQR Announces Second Quarter 2020 Operating and Financial Results
06.08.20
Luna Innovations Reports Solid Second-Quarter 2020 Results
mehr Branchennachrichten »

Aktienkurs Turning Point Therapeutics A2PGMX |

BörsenplatzNasdaq
Letzter Kurs58,70USD
Performance+1,45 %
Kurszeit06.08.20
Eröffnung57,37USD
Tageshoch59,35USD
Tagestief57,30USD
Vortageskurs57,86USD
Volumen174,92 Tsd.Stk.
52-Wochen Hoch72,03USD
52-Wochen Tief31,30USD
Anzahl Trades1.153
Performance 1 Monat-9,49 %
Performance 1 Jahr+50,41 %

Stammdaten zu Turning Point Therapeutics

NameTurning Point Therapeutics Inc
KurznameTurning Pnt Trp
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA2PGMX
SymbolTPTX
BrancheBiotechnologie
LandUSA USA
ReferenzwährungUSD
Aktienanzahl41,34 Mio.
Marktkapitalisierung2,43 Mrd.USD

Performance Turning Point Therapeutics Aktie

ZeitKursPerf.
1 Tag58,70USD
+1,45 %
1 Woche60,60USD
-3,89 %
1 Monat64,35USD
-9,49 %
3 Monate53,82USD
+8,21 %
6 Monate62,45USD
-6,74 %
Lfd. Jahr62,29USD
-6,50 %
1 Jahr38,72USD
+50,41 %
mehr Performancedaten »
Adresse und Kontaktdaten
NameTurning Point Therapeutics Inc
StadtSan Diego, CA
LandUSA USA
Webseitewww.tptherapeutics.com
Aktionäre interessieren sich auch für:
#WertpapierPerf. %
1.
aap Implantate
+1,81
2.
Getinge (B)
-1,51
3.
Paion
-1,01
4.
Vertex Pharmaceuticals
+0,04
5.
Cardiovascular Systems
+12,48
6.
Fennec Pharmaceuticals
-0,80
7.
Cidara Therapeutics
-5,72
8.
Mereo BioPharma Group
-4,17
9.
Allogene Therapeutics
-3,25
10.
Nemaura Medical
-2,81

Emissionsinformationen

Ausgabepreis16,00USD - 18,00USD
Emissionspreis18,000USD
Emissionsvolumen8.823.530Stück
ZeichnungsgebührNein
IPO Anmeldetag21.03.2019
IPO17.04.2019
PlatzierungÖffentlich